AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3655855
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (CMF, CAF, CAFVP)
Trial: 3655855
Drug: Chemotherapy (overall)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (overall)
Trial: 31987106
Drug: Antidiabetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic treatment only (group C)
Trial: 27102821
Drug: Soluble RSV
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble RSV fusion protein (sF) with GLA adjuvant at highest dosage level
Trial: 20735858
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution plus Saccharomyces boulardii
Trial: 20735858
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii
Trial: 20735858
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration therapy plus placebo
Trial: 18474338
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without nesiritide
Trial: 10457394
Drug: Cerebrospinal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid (CSF) filtration daily over five days (group A)
Trial: 10457394
Drug: Riluzole treatment
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole treatment only (group B)
Trial: 2104077
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g sucralfate daily at bedtime
Trial: 2104077
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sucralfate four times daily (q.d.s.)
Trial: 350500
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen twice daily
Trial: 21616771
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate (H-CHO; 60% of daily caloric intake)
Trial: 21616771
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate (L-CHO; 30% of daily caloric intake)
Trial: 16968916
Drug: Malarone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malarone (250 mg atovaquone plus 100 mg proguanil hydrochloride) daily from 1 day before entering the endemic area to 7 days after leaving the endemic area
Trial: 15226514
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment continued for 2 years
Trial: 15226514
Drug: Infliximab infusions
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab infusions every 8 weeks
Trial: 15226514
Drug: Long-term model
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term model for infliximab treatment
Trial: 6719982
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acebutolol and nifedipine
Trial: 26045552
Drug: Myrtus communis
RxNorm normalized name: MYRTUS COMMUNIS TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtus communis L. freeze-dried aqueous extract (1000 mg/d)
Trial: 26045552
Drug: Omeprazol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazol (20 mg/d)
Trial: 26045552
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Myrtus communis and Omeprazol
Trial: 25457739
Drug: Behavioral therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapies
Trial: 20103724
Drug: Topical perillyl
RxNorm normalized name: perilla frutescens top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical perillyl alcohol (POH) cream, low dose (0.76% w/w)
Trial: 20103724
Drug: Topical perillyl
RxNorm normalized name: perilla frutescens top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical perillyl alcohol (POH) cream, high dose
Trial: 16140708
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg/day for 4 weeks, followed by lovastatin 40 mg/day for 20 weeks
Trial: 30990099
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring containing ethinylestradiol 3.47 mg and etonogestrel 11.00 mg
Trial: 30990099
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring containing ethinylestradiol 2.7 mg and etonogestrel 11.7 mg
Trial: 29649978
Drug: Personalized objects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized objects (e.g., cigarette, paper)
Trial: 24268886
Drug: AUDIT administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUDIT administered at baseline with a cut-point of 8 or above
Trial: 24268886
Drug: AUDIT administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUDIT administered at baseline
Trial: 24268886
Drug: Past amphetamine-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past amphetamine-type stimulant (ATS) use
Trial: 22433034
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group) (CR)
Trial: 20708496
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity intervention (20 min of daily exercise in the classroom)
Trial: 18570266
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Pycnogenol per day at meals
Trial: 1906830
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg estriol vaginal tablets
Trial: 6227756
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg trimethoprim at night
Trial: 6227756
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg methenamine hippurate every 12 hours
Trial: 6227756
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine solution, cleansing twice daily
Trial: 24365961
Drug: BeZuHG (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BeZuHG (early discharge followed by home treatment service)
Trial: 18093207
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg daily)
Trial: 19476473
Drug: Metformin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (titrated to 1500 mg daily)
Trial: 17502494
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion (3.3 to 55 pmol/min per 1000 mL forearm volume)
Trial: 17502494
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion (55 pmol/1000 mL per min)
Trial: 17502494
Drug: Oral fludrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludrocortisone (0.3 mg/d for 2 weeks)
Trial: 11641371
Drug: Oral ribose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ribose supplementation (4 doses/day at 4 g/dose)
Trial: 7989402
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate syrup 70 mg/ml administered 20-40 min prior to procedure
Trial: 24006749
Drug: Laminaria jam
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria jam enriched with chromium (20 g daily containing 280 microg of iodine and 66 microg of chromium)
Trial: 24006749
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (comparison group)
Trial: 18356327
Drug: Cocoa flavanol-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol-containing dark chocolate bar with added sterol esters (1.1 g sterol esters per bar)
Trial: 10408591
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with diuretic (hydrochlorothiazide)
Trial: 10408591
Drug: Both ACE
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ACE inhibitors
Trial: 1979188
Drug: Medicamentous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicamentous treatment alone (control group)
Trial: 28056024
Drug: Single-dose 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 400 mg albendazole (for STH-positive mothers)
Trial: 23373620
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg aspirin for 30 days and 180 mg ticagrelor for 1 year
Trial: 21294929
Drug: Xylose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylose (50 g)
Trial: 19696440
Drug: Sublingual house
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual house dust mite (HDM) immunotherapy
Trial: 17355733
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg once daily for 6 months)
Trial: 17355733
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily oral for 6 months)
Trial: 9876598
Drug: Model I
RxNorm normalized name: VIVI Cap Insulin Temperature Shield Multi-Model Insulin Pen Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model I (cumulative percentage of paracetamol dissolved)
Trial: 3072180
Drug: Behavioral interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral interventions (relaxation and biofeedback therapies)
Trial: 26571887
Drug: Medication (estazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (estazolam 1 mg orally)
Trial: 23383959
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg kg(‐1))
Trial: 23383959
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 ml)
Trial: 20189611
Drug: AST-120 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AST-120 treatment (6 g/d)
Trial: 25694653
Drug: LPV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r monotherapy
Trial: 19320241
Drug: Standard triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple-drug regimen
Trial: 12818245
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy (warfarin 10, 7.5, and 5 mg for three consecutive days)
Trial: 12818245
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) administered in a fixed dose of 200 anti-Xa IU/kg body weight in one subcutaneous injection daily
Trial: 10699698
Drug: Adult self-inflatable
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult self-inflatable bag (maximum volume, 1500 ml)
Trial: 10699698
Drug: Paediatric self-inflatable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric self-inflatable bag (maximum volume, 700 ml)
Trial: 8418695
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) administered to the gastric bed (20 Gy using 11 to 15 MeV electrons)
Trial: 8418695
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (gastrectomy alone or resection and postoperative external beam radiotherapy to the upper abdomen (50 Gy using 6 to 10 mV photons))
Trial: 30404599
Drug: Ultrasound-guided lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided lumbar facet joint injections
Trial: 30404599
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose computed tomography (CT) guidance for lumbar facet joint injections
Trial: 26293583
Drug: Silexan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 80 mg once daily for 10 weeks
Trial: 23375194
Drug: Interceptor(®) Flavor
RxNorm normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interceptor(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Trial: 23375194
Drug: Sentinel(®) Flavor
RxNorm normalized name: Sentinel Flavor Tabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Trial: 30661197
Drug: Adalimumab treatment
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab treatment
Trial: 8048859
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 1.0 mg/h of tissue plasminogen activator (group A)
Trial: 8048859
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bolus followed by an infusion of 1.0 mg/h of tissue plasminogen activator (group B)
Trial: 2972631
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) and etofenamate 10% gel, 3‐5 cm daily on the day of TENS therapy, and the same dose twice daily on the other days
Trial: 31216821
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy group
Trial: 27486173
Drug: Aspiration thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration thrombectomy after intravenous alteplase (IAT)
Trial: 27486173
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase alone
Trial: 21737235
Drug: Continuous veno-venous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous veno-venous hemodiafiltration (CVVHDF) and Intravenous furosemide
Trial: 20009055
Drug: Tarenflurbil, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarenflurbil, 800 mg, administered twice a day
Trial: 17335419
Drug: 0.2 mg/mL
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/mL rhBMP‐2
Trial: 17335419
Drug: 0.05 mg/mL
RxNorm normalized name: digoxin 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/mL rhBMP‐2
Trial: 11511121
Drug: Pentasaccharide (low,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasaccharide (low, medium, or high dose) administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously
Trial: 7810083
Drug: Magnesium (Mg)
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (Mg) treatment with 50 mmol Mg for the first 24 hours and 12 mmol Mg for the subsequent 24 hours
Trial: 29128507
Drug: Unloading shoes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unloading shoes (ASICS GEL‐Melbourne OA)
Trial: 26878748
Drug: 1.2% Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Rosuvastatin Gel
Trial: 26878748
Drug: 1.2% Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Atorvastatin Gel
Trial: 23883311
Drug: Terbutaline sulfate
RxNorm normalized name: Terbutaline Sulfate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline sulfate fast dissolving sublingual films
Trial: 23883311
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral tablets
Trial: 20664891
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of ethanol (35 g)
Trial: 17716753
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RV dilation and IVC broadening
Trial: 17083839
Drug: Alpha-adrenoceptor agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenoceptor agonists
Trial: 11869839
Drug: Chronic lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic lisinopril therapy
Trial: 11869839
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of lisinopril
Trial: 10022449
Drug: L‐T4 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 treatment (group A, n = 100) with an initial dose of 150 microg daily
Trial: 10022449
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group B, n = 102)
Trial: 7784246
Drug: DGAVP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGAVP (2 mg single dose)
Trial: 7784246
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with DGAVP (1 mg/day for 2 weeks)
Trial: 7784246
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with DGAVP
Trial: 7784246
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment with DGAVP
Trial: 359246
Drug: Diflunisal 375
RxNorm normalized name: diflunisal 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 375 mg or 500 mg
Trial: 359246
Drug: Diflunisal (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (multiple doses)
Trial: 359246
Drug: Oxyphenbutazone 200
RxNorm normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxyphenbutazone 200 mg t.i.d.
Trial: 29603100
Drug: Dietary zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary zinc intake (7.04 ± 4.28 mg/day)
Trial: 25345953
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg, twice daily, n=36)
Trial: 25345953
Drug: Acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50 mg, three times a day, n=30)
Trial: 22707271
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (1.06 g)
Trial: 20841390
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (1 mg/day)
Trial: 3534570
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg three times daily)
Trial: 29193558
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (SIs), 6.5 to 8.5mm long
Trial: 29193558
Drug: Sinus augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinus augmentation (SA) and implants ≥10mm long
Trial: 29193558
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (SIs)
Trial: 29193558
Drug: Sinus augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinus augmentation (SA)
Trial: 29193558
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (SIs) and Sinus augmentation (SA)
Trial: 27362788
Drug: Tenofovir (TFV)
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir (TFV) 1% gel
Trial: 27362788
Drug: Placebo rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rectal gel
Trial: 24377326
Drug: Methylphenidate (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (low dose: 5 mg × 3)
Trial: 24377326
Drug: Methylphenidate (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (normal dose: 20 mg × 3)
Trial: 18370580
Drug: Weekly reflexology
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly reflexology treatments for 4 weeks
Trial: 7949827
Drug: Proper diagnosis
RxNorm normalized name: Propel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper diagnosis and treatment of hypertensive disorders in pregnancy